← Back To News

Mainsail Partners Invests in Novus Biologicals Leading provider of life sciences products to use additional resources for continued growth

San Francisco, CA (PRWEB) Mainsail Partners, a San Francisco based private equity firm, announced today that it has completed an equity investment in Novus Biologicals, a leading provider of antibodies, peptides, proteins and other reagents for life science research, based in Littleton, CO. Financial details of the transaction have not been released.

Founded in 1996, Novus Biologicals has experienced significant growth and created strong brand awareness in the research community. The company’s catalog of more than 70,000 proprietary and third-party research grade reagents represents one of the largest product portfolios in the world. More than 45,000 customers throughout the world use Novus’ products in the ordinary course of their research.

“We are excited to partner with Mainsail Partners,” said Karen Padgett, founder and Chief Executive Officer, Novus Biologicals. “From the inception of Novus Biologicals, we have achieved tremendous success with new products and in new markets. We believe that Mainsail Partners will provide our company with additional support as we continue to expand our product offering and customer base.”

“Novus Biologicals represents an exciting opportunity for Mainsail Partners,” said Gavin Turner, Managing Partner, Mainsail Partners. “We are pleased to partner with a leading provider of research tools for life sciences and look forward to continued growth in the coming years through a strong collaboration with the company’s management.”

About Novus Biologicals

Novus Biologicals licenses, develops and markets research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with high-quality antibodies, proteins, kits and RNAi for study of protein functions in disease in the key fields of cancer, neuroscience, autophagy and lipid and cardiovascular research. Founded in 1996, Novus Biologicals is headquartered in Littleton, Colorado. For more information, visit: http://www.novusbio.com.

About Mainsail Partners

With approximately $150 million under management, Mainsail Partners is a private equity firm that invests exclusively in profitable, growing companies in the United States and Canada. Mainsail provides both the capital and experience to lead successful management buyouts, recapitalizations and growth equity investments. Drawing on their network and expertise in operations, strategy and finance, Mainsail represents a uniquely attractive partner to help shareholders and management teams realize value in their business. For more information, visit: http://www.mainsailpartners.com